200 related articles for article (PubMed ID: 35571670)
1. A narrative review of five multigenetic assays in breast cancer.
Zeng C; Zhang J
Transl Cancer Res; 2022 Apr; 11(4):897-907. PubMed ID: 35571670
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
3. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
[TBL] [Abstract][Full Text] [Related]
4. Application Of Multigene Panel Detection In Breast Cancer.
Zhao Y; Xiong D; Yang B; Xia S; Zhang X
J Pak Med Assoc; 2023 Sep; 73(9):1862-1868. PubMed ID: 37817699
[TBL] [Abstract][Full Text] [Related]
5. The Clinical Research and Latest Application of Genomic Assays in Early-Stage Breast Cancer.
Chen K; Wu J; Fang Z; Shao X; Wang X
Technol Cancer Res Treat; 2022; 21():15330338221117402. PubMed ID: 36976899
[TBL] [Abstract][Full Text] [Related]
6. Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(10):1-234. PubMed ID: 32284770
[TBL] [Abstract][Full Text] [Related]
7. [A Review Multigene Assays for Clinical Utility in Breast Cancer].
Araki K; Ito Y
Gan To Kagaku Ryoho; 2016 Nov; 43(11):1332-1340. PubMed ID: 27899774
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of multigene profiling assays in early-stage breast cancer.
Chang MC; Souter LH; Kamel-Reid S; Rutherford M; Bedard P; Trudeau M; Hart J; Eisen A;
Curr Oncol; 2017 Oct; 24(5):e403-e422. PubMed ID: 29089811
[TBL] [Abstract][Full Text] [Related]
9. Genomic Assays in Node Positive Breast Cancer Patients: A Review.
Bou Zerdan M; Ibrahim M; Nakib CE; Hajjar R; Assi HI
Front Oncol; 2020; 10():609100. PubMed ID: 33665165
[TBL] [Abstract][Full Text] [Related]
10. MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays.
Li H; Zhu Y; Burnside ES; Drukker K; Hoadley KA; Fan C; Conzen SD; Whitman GJ; Sutton EJ; Net JM; Ganott M; Huang E; Morris EA; Perou CM; Ji Y; Giger ML
Radiology; 2016 Nov; 281(2):382-391. PubMed ID: 27144536
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.
Ward S; Scope A; Rafia R; Pandor A; Harnan S; Evans P; Wyld L
Health Technol Assess; 2013 Oct; 17(44):1-302. PubMed ID: 24088296
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer.
Ma CX; Bose R; Ellis MJ
Adv Exp Med Biol; 2016; 882():125-54. PubMed ID: 26987533
[TBL] [Abstract][Full Text] [Related]
13. Breast Cancer Recurrence Risk Assessment: Is Non-Invasive Monitoring an Option?
Schunkert EM; Zhao W; Zänker K
Biomed Hub; 2018; 3(3):1-17. PubMed ID: 31988964
[TBL] [Abstract][Full Text] [Related]
14. The multigene classifiers 95GC/42GC/155GC for precision medicine in ER-positive HER2-negative early breast cancer.
Naoi Y; Tsunashima R; Shimazu K; Noguchi S
Cancer Sci; 2021 Apr; 112(4):1369-1375. PubMed ID: 33544932
[TBL] [Abstract][Full Text] [Related]
15. Is gene array testing to be considered routine now?
Paik S
Breast; 2011 Oct; 20 Suppl 3():S87-91. PubMed ID: 22015300
[TBL] [Abstract][Full Text] [Related]
16. HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines.
McLemore LE; Albarracin CT; Gruschkus SK; Bassett RL; Wu Y; Dhamne S; Yim I; Lin K; Bedrosian I; Sneige N; Chen H
Breast Cancer Res Treat; 2021 May; 187(1):95-104. PubMed ID: 33813685
[TBL] [Abstract][Full Text] [Related]
17. Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group*
Genet Med; 2016 Aug; 18(8):770-9. PubMed ID: 26681310
[TBL] [Abstract][Full Text] [Related]
18. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.
Henry NL; Somerfield MR; Abramson VG; Ismaila N; Allison KH; Anders CK; Chingos DT; Eisen A; Ferrari BL; Openshaw TH; Spears PA; Vikas P; Stearns V
J Clin Oncol; 2019 Aug; 37(22):1965-1977. PubMed ID: 31206315
[TBL] [Abstract][Full Text] [Related]
19. Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility.
Sinn P; Aulmann S; Wirtz R; Schott S; Marmé F; Varga Z; Lebeau A; Kreipe H; Schneeweiss A
Geburtshilfe Frauenheilkd; 2013 Sep; 73(9):932-940. PubMed ID: 24771945
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
